{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:13:32Z","timestamp":1788527612388,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine and Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.resmer.2026.101317","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:11:03Z","timestamp":1787760663000},"page":"101317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Combined emphysema and cancer, from radiology to prognosis in patients treated by immunotherapy: An ancillary study of a prospective multicenter phase II IFCT-1802 SAVIMMUNE"],"prefix":"10.1016","volume":"90","author":[{"given":"Ma\u00e9va","family":"Zysman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilyes","family":"Benlala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Langlais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Greillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Mascaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Pinquie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Carmier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Roch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Debieuvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Dhalluin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Giroux-Leprieur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Berton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Duruisseaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Raimbourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Rabeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Dixmier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Naltet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Westeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Zalcman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gael","family":"Dournes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gounant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.resmer.2026.101317_bib0001","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with Pembrolizumab versus chemotherapy as first-line therapy in patients with non\u2013Small-cell lung cancer and programmed death ligand-1 tumor proportion score \u2265 1% in the KEYNOTE-042 study","volume":"41","author":"de Castro","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.resmer.2026.101317_bib0002","doi-asserted-by":"crossref","first-page":"989\u20111001","DOI":"10.1016\/S1470-2045(23)00329-7","article-title":"First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial","volume":"24","author":"\u00d6zg\u00fcro\u011flu","year":"2023","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.resmer.2026.101317_bib0003","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.resmer.2026.101317_bib0004","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jtho.2024.10.024","article-title":"Durvalumab versus chemotherapy as first-line treatment for metastatic NSCLC with tumor PD-L1 expression of 25% or higher: results from the randomized phase 3 PEARL study","volume":"20","author":"Lu","year":"2025","journal-title":"J Thorac Oncol Mars"},{"key":"10.1016\/j.resmer.2026.101317_bib0005","article-title":"A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2","volume":"66","author":"Shaverdashvili","year":"2023","journal-title":"EClin Med"},{"issue":"19","key":"10.1016\/j.resmer.2026.101317_bib0006","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.resmer.2026.101317_bib0007","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"54","key":"10.1016\/j.resmer.2026.101317_bib0008","doi-asserted-by":"crossref","first-page":"93149","DOI":"10.18632\/oncotarget.18703","article-title":"Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.resmer.2026.101317_bib0009","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000324601","article-title":"Chronic obstructive pulmonary disease and lung cancer: new molecular insights","volume":"81","author":"Adcock","year":"2011","journal-title":"Respiration"},{"issue":"1","key":"10.1016\/j.resmer.2026.101317_bib0010","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-02251-0","article-title":"COPD patients with non-small cell lung cancer respond better to anti-PD-(L)1 immune checkpoint inhibitors","volume":"15","author":"Boudoussier","year":"2025","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.resmer.2026.101317_bib0011","doi-asserted-by":"crossref","first-page":"00195","DOI":"10.1183\/23120541.00195-2023","article-title":"The association of chest computed tomography-defined visual emphysema and prognosis in patients with nonsmall cell lung cancer","volume":"9","author":"Zhang","year":"2023","journal-title":"ERJ Open Res"},{"issue":"12","key":"10.1016\/j.resmer.2026.101317_bib0012","first-page":"100908","article-title":"Durvalumab in patients with treatment-naive stage IV NSCLC with an ECOG performance status of 2 to 3 and high PD-L1 tumor expression (IFCT-1802 SAVIMMUNE): a multicenter phase 2 trial","volume":"6","author":"Gounant","year":"2025","journal-title":"JTO Clin Res Rep"},{"issue":"7","key":"10.1016\/j.resmer.2026.101317_bib0013","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1164\/rccm.200803-435OC","article-title":"Association of radiographic emphysema and airflow obstruction with lung cancer","volume":"178","author":"Wilson","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.resmer.2026.101317_bib0014","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S2213-2600(13)70006-7","article-title":"The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study","volume":"1","author":"Coxson","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.resmer.2026.101317_bib0015","doi-asserted-by":"crossref","first-page":"32\u201143","DOI":"10.3109\/15412550903499522","article-title":"Genetic epidemiology of COPD (COPDGene) study design","volume":"7","author":"Regan","year":"2011","journal-title":"COPD"},{"issue":"1","key":"10.1016\/j.resmer.2026.101317_bib0016","doi-asserted-by":"crossref","first-page":"192\u2011205","DOI":"10.1148\/radiol.2015141579","article-title":"CT-definable subtypes of Chronic obstructive pulmonary Disease: a statement of the Fleischner Society","volume":"277","author":"Lynch","year":"2015","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.resmer.2026.101317_bib0017","doi-asserted-by":"crossref","first-page":"63\u201170","DOI":"10.1164\/rccm.201408-1423OC","article-title":"Computed tomographic measurement of airway remodeling and emphysema in advanced chronic obstructive pulmonary disease. Correlation with pulmonary hypertension","volume":"191","author":"Dournes","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.resmer.2026.101317_bib0018","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/thoraxjnl-2015-207696","article-title":"CT evaluation of small pulmonary vessels area in patients with COPD with severe pulmonary hypertension","volume":"71","author":"Coste","year":"2016","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.resmer.2026.101317_bib0019","doi-asserted-by":"crossref","first-page":"8881","DOI":"10.1038\/s41598-022-13131-2","article-title":"Quantitative evaluation of emphysema for predicting immunotherapy response in patients with advanced non-small-cell lung cancer","volume":"12","author":"Noda","year":"2022","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.resmer.2026.101317_bib0020","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1164\/rccm.201706-1110OC","article-title":"Impaired tumor-infiltrating T cells in patients with chronic obstructive pulmonary disease impact lung cancer response to PD-1 blockade","volume":"198","author":"Biton","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.resmer.2026.101317_bib0021","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1016\/j.cllc.2020.01.001","article-title":"Performance status and age as predictors of immunotherapy outcomes in advanced non-small-cell lung cancer","volume":"21","author":"Ahmed","year":"2020","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"10.1016\/j.resmer.2026.101317_bib0022","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1378\/chest.10-0185","article-title":"Vascular invasion is a strong prognostic factor after complete resection of node-negative non-small cell lung cancer","volume":"138","author":"Naito","year":"2010","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.resmer.2026.101317_bib0023","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ejrad.2009.03.023","article-title":"Contrast enhanced CT-scans are not comparable to non-enhanced scans in emphysema quantification","volume":"74","author":"Heussel","year":"2010","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.resmer.2026.101317_bib0024","doi-asserted-by":"crossref","first-page":"9262","DOI":"10.1007\/s00330-023-09759-x","article-title":"Development and external validation of a prediction model for the transition from mild to moderate or severe form of COVID-19","volume":"33","author":"Zysman","year":"2023","journal-title":"Eur Radiol"}],"container-title":["Respiratory Medicine and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041226000711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041226000711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:18:31Z","timestamp":1788524311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590041226000711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":24,"alternative-id":["S2590041226000711"],"URL":"https:\/\/doi.org\/10.1016\/j.resmer.2026.101317","relation":{},"ISSN":["2590-0412"],"issn-type":[{"value":"2590-0412","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined emphysema and cancer, from radiology to prognosis in patients treated by immunotherapy: An ancillary study of a prospective multicenter phase II IFCT-1802 SAVIMMUNE","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine and Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resmer.2026.101317","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 SPLF and Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101317"}}